| Specialty Retail Industry | Consumer Discretionary Sector | Dr. Klaus Peter Wilden CEO | SIX Exchange | CH1110760852 ISIN |
| CH Country | 1,273 Employees | 2 May 2022 Last Dividend | - Last Split | - IPO Date |
PolyPeptide Group AG is a distinguished contract development and manufacturing organization (CDMO) with a global footprint spanning Europe, the United States, and India. Specializing in the development and production of synthetic peptides and oligonucleotides, the company plays a pivotal role in supplying active pharmaceutical ingredients (APIs) and intermediates for a wide array of therapeutic products. Founded in 1952 and based in Baar, Switzerland, PolyPeptide Group has established itself as a critical partner for pharmaceutical and biotechnology companies worldwide. With a track record of expertise and innovation in peptide-based therapies, it contributes significantly to advancements in healthcare. The company operates as a subsidiary of Draupnir Holding B.V., further solidifying its position within the pharmaceutical manufacturing landscape.
Peptide-Based Therapies for Metabolic Disorders: PolyPeptide Group specializes in the development of peptide-based therapies to address a variety of metabolic disorders. This includes GLP-1 receptor agonist drugs that are crucial in treating conditions such as type 2 diabetes, obesity, and associated co-morbidities. The company leverages state-of-the-art technology to offer innovative solutions that enhance patient care and outcomes in the field of metabolic health.
Oncology, Hormonal Disorders, Neurology, Ophthalmology, Cardiovascular, and Gastrointestinal Applications: The Group's extensive expertise spans a wide range of therapeutic areas beyond metabolic disorders. It provides tailor-made peptide solutions for treatments in oncology, hormonal imbalances, neurological conditions, eye diseases, heart-related ailments, and gastrointestinal issues. Through a combination of cutting-edge research and development capabilities, PolyPeptide supports the advancement of medical treatments across these vital healthcare sectors.
Cosmetic Peptides: Recognizing the growing demand for high-quality cosmetic ingredients, PolyPeptide has diversified its offerings to include peptides designed specifically for cosmetic applications. These high-purity peptides are used in various skincare and beauty products, offering anti-aging, moisturizing, and reparative benefits, among others. The company's foray into the cosmetics industry demonstrates its adaptability and commitment to meeting the evolving needs of its clients.
Individualized Peptide Therapeutics: In a groundbreaking approach to personalized medicine, PolyPeptide offers services related to individualized peptide therapeutics. This innovative service caters to the specific needs of patients and healthcare providers, enabling the development of customized peptide treatments tailored to the unique genetic and health profiles of individual patients. Through this personalized approach, PolyPeptide is at the forefront of delivering targeted and effective healthcare solutions.